195 related articles for article (PubMed ID: 22932898)
1. A proteasome inhibitor-stimulated Nrf1 protein-dependent compensatory increase in proteasome subunit gene expression reduces polycomb group protein level.
Balasubramanian S; Kanade S; Han B; Eckert RL
J Biol Chem; 2012 Oct; 287(43):36179-89. PubMed ID: 22932898
[TBL] [Abstract][Full Text] [Related]
2. Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97.
Sha Z; Goldberg AL
Curr Biol; 2014 Jul; 24(14):1573-1583. PubMed ID: 24998528
[TBL] [Abstract][Full Text] [Related]
3. (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells.
Choudhury SR; Balasubramanian S; Chew YC; Han B; Marquez VE; Eckert RL
Carcinogenesis; 2011 Oct; 32(10):1525-32. PubMed ID: 21798853
[TBL] [Abstract][Full Text] [Related]
4. The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival.
Balasubramanian S; Adhikary G; Eckert RL
Carcinogenesis; 2010 Mar; 31(3):496-503. PubMed ID: 20015867
[TBL] [Abstract][Full Text] [Related]
5. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
6. Disabling the Protease DDI2 Attenuates the Transcriptional Activity of NRF1 and Potentiates Proteasome Inhibitor Cytotoxicity.
Northrop A; Vangala JR; Feygin A; Radhakrishnan SK
Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31947743
[TBL] [Abstract][Full Text] [Related]
7. Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells.
Radhakrishnan SK; Lee CS; Young P; Beskow A; Chan JY; Deshaies RJ
Mol Cell; 2010 Apr; 38(1):17-28. PubMed ID: 20385086
[TBL] [Abstract][Full Text] [Related]
8. Sulforaphane suppresses polycomb group protein level via a proteasome-dependent mechanism in skin cancer cells.
Balasubramanian S; Chew YC; Eckert RL
Mol Pharmacol; 2011 Nov; 80(5):870-8. PubMed ID: 21807989
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition induces both pro- and anti-cell death pathways in prostate cancer cells.
Yang W; Monroe J; Zhang Y; George D; Bremer E; Li H
Cancer Lett; 2006 Nov; 243(2):217-27. PubMed ID: 16413676
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a.
Qiang W; Sui F; Ma J; Li X; Ren X; Shao Y; Liu J; Guan H; Shi B; Hou P
Endocrine; 2017 Apr; 56(1):98-108. PubMed ID: 28220348
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein.
Yoshida T; Shiraishi T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
Cancer Res; 2005 Jul; 65(13):5662-7. PubMed ID: 15994939
[TBL] [Abstract][Full Text] [Related]
12. Influence of p53 and p21Waf1 expression on G2/M phase arrest of colorectal carcinoma HCT116 cells to proteasome inhibitors.
Kim OH; Lim JH; Woo KJ; Kim YH; Jin IN; Han ST; Park JW; Kwon TK
Int J Oncol; 2004 Apr; 24(4):935-41. PubMed ID: 15010833
[TBL] [Abstract][Full Text] [Related]
13. [Mechanism of G2/M cell cycle arrest before apoptosis in leukemia cell line HL-60 induced by proteasome inhibitor MG132].
Sun GJ; Qian JJ; Meng XB; Song Y; Zhang F; Mei ZZ; Dong Y; Sun ZX
Ai Zheng; 2004 Oct; 23(10):1144-8. PubMed ID: 15473924
[TBL] [Abstract][Full Text] [Related]
14. Nrf1 can be processed and activated in a proteasome-independent manner.
Vangala JR; Sotzny F; Krüger E; Deshaies RJ; Radhakrishnan SK
Curr Biol; 2016 Sep; 26(18):R834-R835. PubMed ID: 27676297
[TBL] [Abstract][Full Text] [Related]
15. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
[TBL] [Abstract][Full Text] [Related]
16. Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells.
Dimri M; Bommi PV; Sahasrabuddhe AA; Khandekar JD; Dimri GP
Carcinogenesis; 2010 Mar; 31(3):489-95. PubMed ID: 19969553
[TBL] [Abstract][Full Text] [Related]
17. The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells.
Giuliano M; Lauricella M; Calvaruso G; Carabillò M; Emanuele S; Vento R; Tesoriere G
Cancer Res; 1999 Nov; 59(21):5586-95. PubMed ID: 10554039
[TBL] [Abstract][Full Text] [Related]
18. p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition.
Radhakrishnan SK; den Besten W; Deshaies RJ
Elife; 2014; 3():e01856. PubMed ID: 24448410
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of heat shock protein expression by proteasome inhibition: an antiapoptotic mechanism in the lens.
Awasthi N; Wagner BJ
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2082-91. PubMed ID: 15914627
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-catenin-mediated transactivation.
Cervello M; Giannitrapani L; La Rosa M; Notarbartolo M; Labbozzetta M; Poma P; Montalto G; D'Alessandro N
Int J Mol Med; 2004 May; 13(5):741-8. PubMed ID: 15067380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
